JNCI-Journal of the National Cancer Institute

Scope & Guideline

Empowering oncologists with groundbreaking insights.

Introduction

Immerse yourself in the scholarly insights of JNCI-Journal of the National Cancer Institute with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN0027-8874
PublisherOXFORD UNIV PRESS INC
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1940 to 2024
AbbreviationJNCI-J NATL CANCER I / JNCI-J. Natl. Cancer Inst.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressJOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513

Aims and Scopes

The JNCI-Journal of the National Cancer Institute serves as a leading platform for disseminating significant advancements in cancer research, focusing on various aspects of cancer biology, prevention, detection, treatment, and survivorship. The journal emphasizes rigorous scientific methodologies and seeks to promote interdisciplinary collaboration in cancer research.
  1. Cancer Epidemiology and Prevention:
    Research focusing on the incidence, distribution, and determinants of cancer in populations, with an emphasis on prevention strategies and public health interventions.
  2. Clinical Trials and Therapeutics:
    Studies evaluating the efficacy and safety of cancer treatments, including novel therapeutic agents, surgical interventions, and radiotherapy.
  3. Genomics and Molecular Biology:
    Exploration of genetic and molecular factors contributing to cancer development and progression, including studies on biomarkers for diagnosis and treatment responses.
  4. Health Disparities and Access to Care:
    Investigations into the impact of social determinants on cancer outcomes, addressing disparities in access to care and treatment across different populations.
  5. Patient-Reported Outcomes and Quality of Life:
    Research assessing the impact of cancer and its treatments on patients' quality of life, including psychosocial aspects and long-term survivorship issues.
  6. Translational Research and Precision Medicine:
    Studies bridging laboratory findings with clinical applications to enhance personalized approaches to cancer prevention, diagnosis, and treatment.
The JNCI is currently highlighting several emerging themes that reflect the evolving landscape of cancer research. These trends are indicative of the journal's responsiveness to contemporary challenges in oncology.
  1. Integration of Artificial Intelligence in Oncology:
    The use of AI and machine learning in cancer diagnosis, treatment planning, and patient management is gaining traction, with studies exploring its potential to enhance clinical outcomes.
  2. Focus on Health Equity and Social Determinants of Health:
    Research examining the social, economic, and environmental factors influencing cancer disparities is on the rise, emphasizing the need for equitable healthcare access and intervention.
  3. Longitudinal Studies on Survivorship:
    Increasing attention is being given to the long-term effects of cancer and its treatment on survivors, including studies that assess quality of life and ongoing health challenges.
  4. Patient-Centered Care and Shared Decision-Making:
    There is a growing emphasis on incorporating patient preferences and experiences into cancer care, promoting shared decision-making processes in treatment options.
  5. Microbiome and Cancer Connections:
    Emerging research exploring the relationship between the microbiome and cancer risk, treatment response, and survivorship is becoming more prevalent.

Declining or Waning

While the JNCI continues to address a broad range of cancer-related topics, certain areas of focus appear to be diminishing based on recent publication trends. This shift may reflect changing priorities in cancer research and emerging areas of interest.
  1. Traditional Chemotherapy Studies:
    There has been a noticeable decline in papers solely focused on traditional chemotherapy regimens, as the field increasingly emphasizes targeted and immunotherapy approaches.
  2. Single-Cancer Focus Studies:
    Research concentrating exclusively on single types of cancer is waning, with a growing trend towards studies that encompass multiple cancer types or comparative effectiveness across cancers.
  3. Basic Science without Clinical Application:
    Basic research studies that do not directly translate into clinical practice or therapeutic implications are becoming less common, as the journal prioritizes translational research.

Similar Journals

Breast Cancer

Transforming insights into impactful breast cancer solutions.
Publisher: SPRINGER JAPAN KKISSN: 1340-6868Frequency: 6 issues/year

Breast Cancer is a prestigious peer-reviewed journal published by SPRINGER JAPAN KK, specializing in the multifaceted domains of oncology and medical pharmacology. With an impressive impact factor and recognized within the Q1 category in multiple areas, including Medicine (miscellaneous), Radiology, and Nuclear Medicine and Imaging, this journal serves as a fundamental resource for cutting-edge research and clinical advancements in breast cancer treatment and care. Its indexed presence in renowned databases like Scopus further affirms its significance, ranking 56th in Radiology and 60th in Pharmacology. The journal aims to bridge the gap between clinical practice and scientific research by publishing original articles, reviews, and case studies that enhance understanding and improve patient outcomes. With converged content available from 1994 to 2024, the journal is dedicated to fostering innovative research while engaging a global audience of researchers, clinicians, and students passionate about tackling breast cancer challenges.

Oncology Letters

Advancing Cancer Research Through Innovative Insights
Publisher: SPANDIDOS PUBL LTDISSN: 1792-1074Frequency: 12 issues/year

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

eCancerMedicalScience

Empowering global collaboration in cancer science.
Publisher: eCancer Global FoundationISSN: 1754-6605Frequency:

eCancerMedicalScience, a leading open-access journal published by the eCancer Global Foundation, is dedicated to advancing the field of cancer research and oncology. With its inception in 2007, this esteemed journal has emerged as a pivotal platform for disseminating groundbreaking research, innovative treatments, and comprehensive reviews in the cancer domain. Based in the United Kingdom, eCancerMedicalScience has continuously contributed to the academic community with its rigorous peer-review process and broad-ranging scope, now encompassing topics from clinical oncology to molecular biology. Currently ranked in the Q3 quartile for both Cancer Research and Oncology in 2023, the journal provides a significant opportunity for researchers, professionals, and students to access valuable insights and share their findings within a global network. The commitment to open access ensures that knowledge is readily available, fostering collaborative efforts to combat cancer and improve patient outcomes.

JOURNAL OF CLINICAL ONCOLOGY

Pioneering breakthroughs in oncology and patient care.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0732-183XFrequency: 36 issues/year

Journal of Clinical Oncology is a premier academic journal published by Lippincott Williams & Wilkins, dedicated to the field of oncology and cancer research. Since its inception in 1983, this influential journal has consistently ranked in the Q1 category across multiple disciplines, including cancer research, medicine, and oncology, reflecting its critical role in shaping the future of cancer therapeutics and patient care. With a Scopus ranking of #9 in Medicine - Oncology and #6 in Biochemistry, Genetics and Molecular Biology - Cancer Research, Journal of Clinical Oncology publishes cutting-edge original research, reviews, and clinical updates that are essential for professionals, researchers, and students alike. Although it does not currently offer open access options, it provides invaluable insights and evidence-based findings that are crucial for advancing oncological knowledge and improving patient outcomes globally. The journal’s continued commitment to excellence ensures its place as a vital resource in the oncological community.

CANCER INVESTIGATION

Unraveling the complexities of cancer through rigorous inquiry.
Publisher: TAYLOR & FRANCIS INCISSN: 0735-7907Frequency: 10 issues/year

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

Journal of the Egyptian National Cancer Institute

Bridging gaps in cancer knowledge for a healthier tomorrow.
Publisher: SPRINGERISSN: 1110-0362Frequency: 1 issue/year

Journal of the Egyptian National Cancer Institute, published by SPRINGER, serves as a vital platform for disseminating innovative research in the field of oncology and cancer research. With both ISSN 1110-0362 and E-ISSN 2589-0409, this Open Access journal has been committed to making significant contributions to the scientific community since its inception in 2005. Operating from its base in Egypt, it has established itself as an important resource for researchers, practitioners, and students alike, offering insights into contemporary issues and advancements in cancer care. Recognized in the 2023 category quartiles as Q3 in Cancer Research and Q3 in Oncology, the journal is positioned to impact the ongoing discourse in cancer treatment strategies and health policy. As it continues to publish peer-reviewed articles through available Open Access avenues, the Journal of the Egyptian National Cancer Institute remains dedicated to enhancing the knowledge base and collaborative efforts within the global cancer research community.

Cancer Medicine

Connecting global minds for impactful cancer research.
Publisher: WILEYISSN: 2045-7634Frequency: 12 issues/year

Cancer Medicine is a leading open access journal published by WILEY, focusing on innovative research and advancements in the fields of Cancer Research, Oncology, and Radiology, with an impressive impact evidenced by its 2023 Q2 ranking in Cancer Research and Q1 rankings in both Oncology and Radiology, Nuclear Medicine and Imaging. With an ISSN of 2045-7634, this journal has been committed to disseminating pivotal findings since its inception in 2012, serving as a vital platform for researchers, practitioners, and students alike. The journal proudly embodies the spirit of open access, ensuring that groundbreaking cancer research is accessible to a global audience. Located in the United Kingdom, it spans a wide array of topics, promising comprehensive insights into cancer therapies, molecular mechanisms, and imaging techniques, thereby significantly contributing to the enhancement of cancer care and treatment outcomes. Researchers interested in exploring the latest advancements in cancer medicine will find this journal an indispensable resource.

Cancers

Fostering collaboration in the fight against cancer.
Publisher: MDPIISSN: Frequency: 24 issues/year

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

Oncology Reviews

Pioneering Knowledge in Oncology and Beyond
Publisher: FRONTIERS MEDIA SAISSN: 1970-5557Frequency: 2 issues/year

Oncology Reviews, founded in 2007 and published by FRONTIERS MEDIA SA, is a leading open-access journal dedicated to advancing knowledge in the field of oncology and cancer research. With an Impact Factor reflecting its robust engagement in scholarly discourse, this journal maintains a prestigious standing, earning a Q2 ranking in Oncology and a Q3 ranking in Cancer Research as of 2023. Notably, it is indexed in Scopus, where it ranks #118 in Oncology and #98 in Cancer Research, highlighting its global reach and significance. The journal's open-access policy, in effect since 2012, ensures that high-quality research is accessible to all, fostering collaboration and wellness improvements worldwide. This commitment to accessibility and dissemination of pivotal research makes Oncology Reviews an essential resource for researchers, healthcare professionals, and students eager to contribute to and stay abreast of the latest innovations in cancer treatment and research.

LANCET ONCOLOGY

Unveiling breakthroughs in oncology and patient care.
Publisher: ELSEVIER SCIENCE INCISSN: 1470-2045Frequency: 12 issues/year

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.